BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28906028)

  • 1. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
    Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
    Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
    Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
    Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
    Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
    Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
    Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
    Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
    Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
    Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
    Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
    Bitzan M; Ouahed JD; Carpineta L; Bernard C; Bell LE
    Pediatr Nephrol; 2010 Jun; 25(6):1163-7. PubMed ID: 20140460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.